Get the Stockscreener App
722.83
0.12%
-0.84
After Hours:
722.80
-0.03
-0.00%
Regeneron Pharmaceuticals Inc stock is traded at $722.83, with a volume of 737.14K.
It is down -0.12% in the last 24 hours and up +15.10% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$723.67
Open:
$732.45
24h Volume:
737.14K
Relative Volume:
0.68
Market Cap:
$75.97B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
17.30
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
-7.87%
1M Performance:
+15.10%
6M Performance:
+49.06%
1Y Performance:
-4.17%
1-Day Range:
$721.22
$735.00
1-Week Range:
$720.07
$788.98
52-Week Range:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Can Regeneron Pharmaceuticals Inc. stock sustain institutional interestMarket Volume Report & Weekly Top Stock Performers List - Newser
Market Whales and Their Recent Bets on REGN Options - Benzinga
REGN: BMO Capital Raises Price Target and Maintains Outperform R - GuruFocus
BMO Capital raises Regeneron Pharma stock price target to $850 on Dupixent growth - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to "Equal Weight" at Morgan Stanley - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Lido Advisors LLC - MarketBeat
How Does Regeneron Pharmaceuticals Stock Stack Up Against Its Peers? - Trefis
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Schroder Investment Management Group - MarketBeat
Canaccord Genuity Adjusts PT on Regeneron Pharmaceuticals to $1,057 From $850, Maintains Buy Rating - marketscreener.com
Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Groupe la Francaise - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock sustain high P E ratiosMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
Jim Cramer on Regeneron: “They’re Doing a Lot of Good Stuff, I Lost Sight of It, I Shouldn’t Have” - Insider Monkey
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsJuly 2025 Retail & Free High Return Stock Watch Alerts - Newser
Regeneron Shares Fall After Morgan Stanley Downgrade - marketscreener.com
Morgan Stanley Downgrades Regeneron (REGN) Citing Fair Valuation - GuruFocus
Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny - Markets Financial Content
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron - ts2.tech
Regeneron downgraded at Morgan Stanley on valuation level - Seeking Alpha
REGN: Morgan Stanley Downgrades Regeneron Pharmaceuticals Rating to Equal-Weight | REGN Stock News - GuruFocus
Regeneron Shares Now Reflect Valuation as Pipeline Visibility Becomes Key, Morgan Stanley Says - marketscreener.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Merck & Company (MRK) and Regeneron (REGN) - The Globe and Mail
Morgan Stanley Downgrades Regeneron Pharmaceuticals to Equalweight From Overweight, PT is $767 - marketscreener.com
Vascular Endothelial Growth Factor Receptor (VEGFR) - openPR.com
Edgestream Partners L.P. Has $5.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Canaccord Genuity Raises Price Target for Regeneron Pharmaceuticals (REGN) to $1,057 | REGN Stock News - GuruFocus
Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - BioCentury
COPD Market to Expand Significantly by 2034, States DelveInsight Report | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZeneca - Barchart.com
Follicular Lymphoma Market Predicted to See Upsurge Through - openPR.com
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD - Yahoo Finance Singapore
Akeso’s Goals Beyond Ivonescimab: ‘We Can Hit Vertex And Regeneron-Level Innovation’ - Citeline News & Insights
Research Alert: CFRA Retains Buy Rating On Shares Of Regeneron Pharmaceuticals, Inc. - 富途牛牛
Regeneron and Tessera partner to develop gene therapy for AATD - MarketScreener
Regeneron and Tessera ink $150M gene editing partnership in AATD - The Pharma Letter
Regeneron stock maintains Outperform rating at Bernstein following Tessera deal - Investing.com UK
Regeneron Pharmaceuticals, Inc. $REGN Stake Increased by Mackenzie Financial Corp - MarketBeat
Sepio Capital LP Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Wall Street predicts for Regeneron Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & AI Enhanced Trading Signals - Newser
Quadrant Capital Group LLC Sells 688 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Distillate Capital Partners LLC Has $14.69 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN): Is There More Value Ahead After Recent Uptrend? - simplywall.st
Can Regeneron Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Institutional & High Accuracy Buy Signal Tips - Newser
Will Regeneron Pharmaceuticals Inc. (RGO) stock benefit from sector leadershipNew Guidance & Smart Allocation Stock Reports - Newser
Tessera Will Team With Regeneron On Gene-Writing Therapy For AATD - Citeline News & Insights
Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder - MedCity News
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron (REGN) Invests $150M in Tessera's Gene Editing Therapy - GuruFocus
Regeneron inks deal with Tessera to develop gene editing therapy - Seeking Alpha
Regeneron and Tessera advance TSRA-196 toward IND/CTA filings - CRISPR Medicine News
Regeneron and Tessera join forces to forge in vivo AATD gene therapy - Yahoo Finance
Somerville biotech secures $150M upfront from Regeneron for gene-editing treatment - The Business Journals
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):